Atossa Genetics Files Again for IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.